The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
The impact of antibodies on clinical outcomes in diseases treated with therapeutic protein: Lessons learned from infantile Pompe disease
Open accessAbstract
Purpose: Enzyme replacement therapy with rhGAA (Myozyme®) has lead to improved survival, which is largely attributable to improvements in cardiomyopathy and skeletal muscle function. However, crossreactive immunologic material-negative patients have a poor clinical response to enzyme replacement therapy secondary to high sustained antibody titers. Furthermore, although the majority of crossreactive immunologic material-positive patients tolerize or experience a downtrend in anti-rhGAA antibody titers, antibody response is variable with some crossreactive immunologic material-positive infants also mounting high sustained antibody titers.Methods: We retrospectively analyzed 34 infants with Pompe disease: 11 crossreactive immunologic material-negative patients, nine high-titer crossreactive immunologic material-positive patients, and 14 low-titer crossreactive immunologic material-positive patients. Clinical outcome measures were overall survival, ventilator-free survival, left ventricular mass index, Alberta Infant Motor Scale score, and urine Glc4 levels.Results: Clinical outcomes in the high-titer crossreactive immunologic material-positive group were poor across all areas evaluated relative to the low-titer crossreactive immunologic material-positive group. For the crossreactive immunologic material-negative and high-titer crossreactive immunologic material-positive groups, no statistically significant differences were observed for any outcome measures, and both patient groups did poorly.Conclusions: Our data indicate that, irrespective of crossreactive immunologic material status, patients with infantile Pompe disease with high sustained antibody titer have an attenuated therapeutic response to enzyme replacement therapy. With the advent of immunomodulation therapies, identification of patients at risk for developing high sustained antibody titer is critical.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
Recombinant human acid α-glucosidase: Major clinical benefits in infantile-onset Pompe disease
Kishnani, P. S., Corzo, D., Nicolino, M., Byrne, B., Mandel, H., Hwu, W. L., Leslie, N., Levine, J., Spencer, C., McDonald, M., et al. (2007) · Neurology · doi:10.1212/01.wnl.0000251268.41188.04 · Cited by 781
Self-citationA Randomized Study of Alglucosidase Alfa in Late-Onset Pompe's Disease
van der Ploeg, A. T., Clemens, P. R., Corzo, D., Escolar, D. M., Florence, J., Groeneveld, G. J., Herson, S., Kishnani, P. S., Laforet, P., Lake, S. L., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0909859 · Cited by 745
Self-citationEnzyme-Replacement Therapy in Mucopolysaccharidosis I
Kakkis, E. D., Muenzer, J., Tiller, G. E., Waber, L., Belmont, J., Passage, M., Izykowski, B., Phillips, J., Doroshow, R., Walot, I., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200101183440304 · Cited by 667
Kishnani, P. S., Hwu, W.-L., Mandel, H., Nicolino, M., Yong, F., & Corzo, D. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2005.11.033 · Cited by 598
Self-citationvan den Hout, H. M. P., Hop, W., van Diggelen, O. P., Smeitink, J. A. M., Smit, G. P. A., Poll-The, B.-T. T., Bakker, H. D., Loonen, M. C. B., de Klerk, J. B. C., Reuser, A. J. J., et al. (2003) · Pediatrics · doi:10.1542/peds.112.2.332 · Cited by 555
Motor Assessment of the Developing Infant
Piper, M. C., & Darrah, J. (1994) · Medical Entomology and Zoology · Cited by 498
Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants
Kishnani, P. S., Goldenberg, P. C., DeArmey, S. L., Heller, J., Benjamin, D., Young, S., Bali, D., Smith, S. A., Li, J. S., Mandel, H., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2009.08.003 · Cited by 383
Self-citationAmalfitano, A., Bengur, A. R., Morse, R. P., Majure, J. M., Case, L. E., Veerling, D. L., Mackey, J., Kishnani, P., Smith, W., McVie-Wylie, A., et al. (2001) · Genetics in Medicine · doi:10.1038/gim200127 · Cited by 347
Self-citationEarly Treatment With Alglucosidase Alfa Prolongs Long-Term Survival of Infants With Pompe Disease
Kishnani, P. S., Corzo, D., Leslie, N. D., Gruskin, D. J., van der Ploeg, A., Clancy, J. P., Parini, R., Morin, G., Beck, M., Bauer, M., et al. (2009) · Pediatric Research · doi:10.1203/pdr.0b013e3181b24e94 · Cited by 343
Self-citationIncidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis
Rudick, R. A., Simonian, N. A., Alam, J. A., Campion, M., Scaramucci, J. O., Jones, W., Coats, M. E., Goodkin, D. E., Weinstock-Guttman, B., Herndon, R. M., et al. (1998) · Neurology · doi:10.1212/wnl.50.5.1266 · Cited by 333
Nicolino, M., Byrne, B., Wraith, J. E., Leslie, N., Mandel, H., Freyer, D. R., Arnold, G. L., Pivnick, E. K., Ottinger, C. J., Robinson, P. H., et al. (2009) · Genetics in Medicine · doi:10.1097/gim.0b013e31819d0996 · Cited by 293
Self-citationKishnani, P. S., Nicolino, M., Voit, T., Rogers, R. C., Tsai, A. C.-H., Waterson, J., Herman, G. E., Amalfitano, A., Thurberg, B. L., Richards, S., et al. (2006) · The Journal of Pediatrics · doi:10.1016/j.jpeds.2006.02.035 · Cited by 282
Self-citationHuman Immune Response to Recombinant Human Proteins
Porter, S. (2001) · Journal of Pharmaceutical Sciences · doi:10.1002/1520-6017(200101)90:1<1::aid-jps1>3.0.co;2-k · Cited by 183
Klinge, L., Straub, V., Neudorf, U., Schaper, J., Bosbach, T., Görlinger, K., Wallot, M., Richards, S., & Voit, T. (2005) · Neuromuscular Disorders · doi:10.1016/j.nmd.2004.10.009 · Cited by 179
How we treat a hemophilia A patient with a factor VIII inhibitor
Kempton, C. L., & White, G. C. (2009) · Blood · doi:10.1182/blood-2008-06-160432 · Cited by 163
Vedder, A. C., Breunig, F., Donker‐Koopman, W. E., Mills, K. A., Young, E. P., WINCHESTER, B. G., ten Berge, I. J. M., Groener, J. E. M., Aerts, J. M. F. G., Wanner, C., et al. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.03.003 · Cited by 137
Elimination of Antibodies to Recombinant Enzyme in Pompe's Disease
Mendelsohn, N. J., Messinger, Y. H., Rosenberg, A. S., & Kishnani, P. S. (2009) · New England Journal of Medicine · doi:10.1056/nejmc0806809 · Cited by 136
Self-citationSun, B., Bird, A., Young, S. P., Kishnani, P. S., Chen, Y.-T., & Koeberl, D. D. (2007) · The American Journal of Human Genetics · doi:10.1086/522236 · Cited by 130
Self-citationAntibodies against rHuEPO: native and recombinant
Casadevall, N. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.suppl_5.42 · Cited by 122
Deconstructing Pompe Disease by Analyzing Single Muscle Fibers: “To See a World in a Grain of Sand…”
Raben, N., Takikita, S., Pittis, M. G., Bembi, B., Marie, S. K. N., Roberts, A., PAGE, L. C., Kishnani, P. S., Schoser, B. G. H., Chien, Y., et al. (2007) · Autophagy · doi:10.4161/auto.4591 · Cited by 112
Self-citationDickson, P., Peinovich, M., McEntee, M. F., et al. (2008) · Journal of Clinical Investigation · doi:10.1172/jci34676 · Cited by 108
High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa
de Vries, J. M., van der Beek, N. A. M. E., Kroos, M. A., Özkan, L., van Doorn, P. A., Richards, S. M., Sung, C., Brugma, J.-D. C., Zandbergen, A. A. M., van der Ploeg, A. T., et al. (2010) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2010.08.009 · Cited by 106
Young, S. P., Stevens, R. D., An, Y., Chen, Y., & Millington, D. S. (2003) · Analytical Biochemistry · doi:10.1016/s0003-2697(03)00056-3 · Cited by 77
Self-citationRichards, S., Olson, T., & McPherson, J. (1993) · Blood · doi:10.1182/blood.v82.5.1402.1402 · Cited by 75
Rougeot, C., Marchand, P. M., DRAY, F., Girard, F., Job, J. C., Pierson, M., Ponté, C., ROCHICCIOLI, P. E., & Rappaport, R. (2008) · Hormone Research · doi:10.1159/000181877 · Cited by 43
Hawes, M. L., Kennedy, W., O'Callaghan, M. W., & Thurberg, B. L. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.04.018 · Cited by 39
Turner, C. T., Hopwood, J. J., & Brooks, D. A. (2000) · Molecular Genetics and Metabolism · doi:10.1006/mgme.2000.2979 · Cited by 36
Raben, N., Nagaraju, K., Lee, A., Lu, N., Rivera, Y., Jatkar, T., Hopwood, J. J., & Plötz, P. H. (2003) · Transgenic Research · doi:10.1023/a:1022998010833 · Cited by 32
Richards, S. M. (2002) · Clinical and Applied Immunology Reviews · doi:10.1016/s1529-1049(02)00049-1 · Cited by 32
Immune response to enzyme replacement therapy in Fabry disease: Impact on clinical outcome?
Hollak, C. E. M., & Linthorst, G. E. (2008) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2008.10.013 · Cited by 29
Advances in Hemophilia: Experimental Aspects and Therapy
Rodriguez, N. I., & Hoots, W. K. (2008) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2008.01.010 · Cited by 19
Cited by
Transcription factor EB (TFEB) is a new therapeutic target for Pompe disease
Spampanato, C., Feeney, E., Li, L., Cardone, M., Lim, J., Annunziata, F., Zare, H., Polishchuk, R., Puertollano, R., Parenti, G., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201202176 · Cited by 341
“…response to the recombinant enzyme in cross-reactive immunologic material (CRIM)-negative patients and the presence of large areas of autophagic build-up alongside expanded lysosomes (Banugaria et al, 2011; Funk et al, 1992; Kishnani et al, 2010; Koeberl et al, 2012; Raben et al, 2002, 2010, 2012).”
Immunogenicity to Therapeutic Proteins: Impact on PK/PD and Efficacy
Chirmule, N., Jawa, V., & Meibohm, B. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9340-y · Cited by 335
Desnick, R. J., & Schuchman, E. H. (2012) · Annual Review of Genomics and Human Genetics · doi:10.1146/annurev-genom-090711-163739 · Cited by 269
Glycogen Metabolism and Glycogen Storage Disorders
Kanungo, S., Wells, K., Tribett, T., & El-Gharbawy, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.10.59 · Cited by 200
Pratt, K. P. (2018) · Antibodies · doi:10.3390/antib7020019 · Cited by 96
Metadata
- Authors
- Banugaria, S. G., Prater, S. N., Ng, Y.-K., Kobori, J. A., Finkel, R. S., Ladda, R. L., Chen, Y.-T., Rosenberg, A. S., & Kishnani, P. S.
- Venue
- Genetics in Medicine
- Publisher
- Elsevier BV
- Published
- 2011-08
- Volume
- 13
- Issue
- 8
- Pages
- 729-736
- ISSN
- 1098-3600 (ISSN-L)
- OpenAlex
- W2143609092
- Cited by
- 255
- References
- 32
- FWCI
- 10.79
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.